Business Wire

Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment

Share

Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, announces the European launch of its MDR-cleared next-generation TBS Osteo Advanced software. Following the product launch in the United States last month, this next milestone reflects the company's commitment to advancing osteoporosis detection and bone health management worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702082335/en/

Medimaps' TBS Osteo next-generation software

The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational efficiency, streamline clinical processes, and ensure consistent patient care.

TBS Osteo is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. This approach ensures healthcare organizations stay up to date with the latest innovations in osteoporosis care. Current TBS Osteo users have the possibility to upgrade to the next generation version and to take advantage of the new capabilities.

“The TBS Osteo next-generation software has been developed with busy radiology professionals in mind for a maximum of clinical output with a minimum of logistics. The software is seamlessly integrated into the clinical workflow and performed at time of DXA scan. This approach sets TBS Osteo apart from competition,” said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. “TBS Osteo delivers within seconds a comprehensive report combining BMD and clinical factors, providing results beyond the standard of care. Adopted by many top hospitals across the world, including in the U.S., DXA and TBS Osteo have become the gold standard to detect and monitor osteoporosis.”

Since its initial launch in 2012, TBS Osteo has been widely adopted across the world, to support the assessment and management of osteoporosis. The software is backed by over 1,400 peer-reviewed publications and endorsed by more than 30 national and international osteoporosis assessment and management guidelines.

In Europe, the software has received clearance from the Medical Device Regulation (MDR) and remains the only approved medical software for bone microarchitecture evaluation in clinical practice.

Osteoporosis is a condition that weakens bones and increases the risk of fractures. Fractures due to osteoporosis have a devastating impact on millions of people worldwide and result in enormous socio-economic costs to society and healthcare systems.

According to the International Osteoporosis Foundation, approximately 32 million Europeans aged 50 or over have osteoporosis. The annual number of osteoporotic fractures across the European Union, Switzerland, and the United Kingdom is projected to rise from 4.33 million in 2019 to 5.34 million by 2034 - an increase of over 1 million fractures annually¹. Despite the availability of effective treatments to reduce fracture risk, only 1 in 5 patients who experience an osteoporotic fracture are diagnosed or receive appropriate therapy¹.

References

  1. International Osteoporosis Foundation (IOF), https://www.osteoporosis.foundation/facts-statistics/key-statistic-for-europe, Last accessed: June 24, 2025

About Medimaps Group

Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management.​ We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment.

Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company’s DNA.​

Medimaps Group, headquartered in Geneva, Switzerland, has offices in the United States and France. Its U.S. affiliate, Medimaps Group USA LLC, markets the company products and services.

Learn more at www.medimaps.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20250702082335/en/

Contacts

Saoyuth Nidh
Global Corporate Communications Manager
Mob: +41 79 969 77 57
snidh@medimapsgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 12:13:00 EEST | Press release

SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag

Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release

The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China

The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release

The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate

Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release

Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac

Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye